Who
Krishnan Viswanadhan
Chief Strategy and Operations
Company insider
Files Form 4 as: Chief Strategy and Operations, Agios Pharmaceuticals; Director, CARGO Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $370K
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 9 Nov 2023
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Mar – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,000 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $103K2,959 at $34.71 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 2 Apr 2026filed 6 Apr 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $103K2,959 at $34.71 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K2,959 at $27.80 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Code M | —8,100 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | AGIO Agios PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $82K2,959 at $27.80 | filing |
| 1 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | AGIO Agios Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,000 at $0.00 | filing |
News
Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sarah Gheuens Sells 500 Shares of Company StockAGIO · dailypolitical.com · 23 Oct 2026Contrasting Revolution Medicines (NASDAQ:RVMD) and Agios Pharmaceuticals (NASDAQ:AGIO)AGIO · themarketsdaily.com · 22 Oct 2026
0 headlines in the last 90 days name Krishnan Viswanadhan; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.